The UK beauty market is forecast to reach £59.3bn in 2026, growing at roughly 7% a year. That number is both an invitation and a warning: a growing market attracts launches, and most of them are not ready. This is the sequence we would follow if we were starting again, in the order the decisions actually need to be made.
1. Choose a position you can defend for three years
British consumers have become unusually well informed. Three data points frame the market: 46% now treat health and beauty as essentials rather than discretionary, 32% deliberately buy dupes, and 82% want solutions that feel personally relevant. The result is a customer who will pay a premium — but only for something specific.
The positions working in 2026 are not novel, they are narrow:
- Barrier and skin longevity — ceramides, ectoin, physiological lipid ratios, and claims about barrier function rather than “anti-ageing”.
- Perimenopause and 40+ — now a £2bn category in the UK and US, with dedicated retail space at Boots and Space NK. This customer reads labels and rejects generic repositioning.
- Clinical honesty — plain packaging, one hero ingredient, evidence at the stated concentration. It outperforms maximalist luxury at the same price point.
If your position cannot be explained in one sentence a pharmacist would accept, it is not a position yet.
2. Decide how the product gets made, before you design anything
There are four routes and they are not interchangeable: independent consultancy, ODM (we develop, you brand), OEM (you bring the formula, we manufacture) and OBM (the brand is built end to end). The choice determines who owns the formula, who carries development risk, and what your minimum order will be.
Most founders arrive asking for a manufacturer. What they need first is a costed answer to a simpler question: what will this product cost to make at a volume I can actually sell? A £42 retail serum has roughly £4–£6 of formulation and fill in it if it is to carry a healthy margin, retail VAT and marketing. That constraint decides the formula, not the other way round.
3. Build the product properly, including the boring tests
A formulation is not finished when it feels right on the back of your hand. It is finished when it has passed stability testing at elevated temperature, packaging compatibility, and — for any water-based product — a preservative efficacy (challenge) test. Add microbiological testing and, where relevant, a compatibility check with the pump or dropper.
Budget 4–8 weeks for bench development and 4–8 weeks for testing, running in parallel with packaging selection. Brands that skip the pilot batch usually discover the problem on the commercial run, where it costs a container rather than a beaker.
4. Choose packaging with the 2026 fee schedule in view
Packaging is now a recurring statutory cost, not a one-off purchase. Under GB extended producer responsibility, illustrative Year 2 fees per tonne run from about £190 for green-rated paper to £545 for red-rated plastic. A plastic insert inside a board carton can reclassify the whole unit.
Three practical moves reduce both cost and risk: keep the primary pack mono-material, replace plastic inserts with board, and remove secondary packaging that serves no function. All three are calculable before you specify, and none of them require a design compromise.
5. Get the compliance route right the first time
Great Britain runs its own regime. Before a product can legally be sold you need a GB-established Responsible Person, a Cosmetic Product Safety Report signed by a qualified assessor, a Product Information File in English held for ten years, an SCPN notification, and a label that matches the file.
2026 added moving parts: the Responsible Person’s name and address must appear on the label; 4-MBC has been prohibited since 15 July 2026; sixteen CMR substances, including TPO used in gel and nail products, are prohibited from 15 August 2026; and the formaldehyde-releaser warning threshold dropped to 0.001%. A formula that was compliant in 2024 is not automatically compliant now.
6. Model the whole cost, not the unit price
Indicative planning ranges for a first UK launch, drawn from current market quotes. Treat them as a framework, not a quotation.
| Line | Typical range | Notes |
|---|---|---|
| Formulation development | £3,000–£8,000 per SKU | Higher for actives, SPF or complex emulsions |
| Testing | £1,500–£4,000 per SKU | Stability, compatibility, challenge, micro |
| Safety assessment and PIF | £250–£800 per product | Variants are cheaper; complex products are not |
| Packaging | £0.80–£3.50 per unit | Stock components with decoration, at 1,000–3,000 units |
| Tooling | £0–£6,000 | Only if a bespoke component is genuinely required |
| First stock | £8,000–£30,000 | Usually the largest line, and the one that ties up cash |
A five-SKU skincare range at 1,000–3,000 units per SKU is a five-figure project before marketing. Anyone quoting less is either using stock formulas or excluding a line.
7. Plan for twelve to twenty-four weeks
Not because the work is slow, but because stability, packaging lead times and safety assessment each consume calendar time that cannot be compressed. The two places launches lose a month are predictable: artwork produced before the safety report exists, and packaging ordered before a fill trial.
What actually goes wrong
- Claims written before the formula, then quietly dropped when testing arrives.
- A stock base presented as bespoke, with no differentiation and no defensible story.
- An opening order sized to a factory’s minimum rather than to first-year sell-through.
- A label that does not match the safety report — the most common enforcement finding.
The brands that succeed in this market are rarely the ones with the most innovative formula. They are the ones whose product, price, pack and paperwork all point in the same direction.
If you have a concept and a price point, a paid assessment will tell you what it costs to make, what it can legally claim, and which route gets it to shelf fastest. That is usually two weeks and a fraction of the cost of one wrong decision.
Where this sits in a real project
The sequence above is the one we work through on a paid beauty development consultancy engagement: position, cost model, route, then specification. Where a brand is being built from nothing, OBM incubation runs the same steps with the naming and packaging work added. The regulatory side is set out in UK compliance, and a printable version of the gate checks is in the launch readiness checklist. Our process shows who owns each decision and when.
Questions we are asked
How long does a first UK launch realistically take?
Twelve to twenty-four weeks from an approved formula to a finished first production run. Stability testing, packaging lead times and safety assessment consume calendar time that cannot be compressed, and artwork produced before the safety report is the most common cause of a lost month.
Do I need a UK Responsible Person before I can sell?
Yes. A GB-established Responsible Person must be appointed, the Cosmetic Product Safety Report signed, the Product Information File held in English and the product notified through the SCPN service. We coordinate the appointment and prepare the file; we are not ourselves GB-established.
Can I launch with fewer than 1,000 units per product?
Often, for a stock base with your own labelling. A custom formulation in a stock component usually starts around 1,000 units per SKU; complex or tooled formats start higher. The pack and the changeover drive the number, not a policy.